Abstract:Coronavirus disease 2019 (COVID-19) is rapidly spreading. Researchers around the world are dedicated to finding the treatment clues for COVID-19. Drug repositioning, as a rapid and cost-effective way for finding therapeutic options from available FDA-approved drugs, has been applied to drug discovery for COVID-19. In this study, we develop a novel drug repositioning method (VDA-KLMF) to prioritize possible anti-SARS-CoV-2 drugs integrating virus sequences, drug chemical structures, known Virus-Drug Associations, and Logistic Matrix Factorization with Kernel diffusion. First, Gaussian kernels of viruses and drugs are built based on known VDAs and nearest neighbors. Second, sequence similarity kernel of viruses and chemical structure similarity kernel of drugs are constructed based on biological features and an identity matrix. Third, Gaussian kernel and similarity kernel are diffused. Forth, a logistic matrix factorization model with kernel diffusion is proposed to identify potential anti-SARS-CoV-2 drugs. Finally, molecular dockings between the inferred antiviral drugs and the junction of SARS-CoV-2 spike protein-ACE2 interface are implemented to investigate the binding abilities between them. VDA-KLMF is compared with two state-of-the-art VDA prediction models (VDA-KATZ and VDA-RWR) and three classical association prediction methods (NGRHMDA, LRLSHMDA, and NRLMF) based on 5-fold cross validations on viruses, drugs, and VDAs on three datasets. It obtains the best recalls, AUCs, and AUPRs, significantly outperforming other five methods under the three different cross validations. We observe that four chemical agents coming together on any two datasets, that is, remdesivir, ribavirin, nitazoxanide, and emetine, may be the clues of treatment for COVID-19. The docking results suggest that the key residues K353 and G496 may affect the binding energies and dynamics between the inferred anti-SARS-CoV-2 chemical agents and the junction of the spike protein-ACE2 interface. Integrating various biological data, Gaussian kernel, similarity kernel, and logistic matrix factorization with kernel diffusion, this work demonstrates that a few chemical agents may assist in drug discovery for COVID-19.

Probing antiviral drugs against SARS-CoV-2 through virus-drug association prediction based on the KATZ method

Identifying Effective Antiviral Drugs Against SARS-CoV-2 by Drug Repositioning Through Virus-Drug Association Prediction.

A Search for Medications to Treat COVID-19 Via in Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease

Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures

VDA-RWLRLS: an Anti-Sars-cov-2 Drug Prioritizing Framework Combining an Unbalanced Bi-Random Walk and Laplacian Regularized Least Squares

Discovery of Potential Therapeutic Drugs for COVID-19 Through Logistic Matrix Factorization with Kernel Diffusion.

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

Structure-based virtual screening and molecular docking of drugs against the SARS-CoV-2 spike protein-ACE2 receptor complex

Identification of Therapeutic Drugs Against COVID-19 Through Computational Investigation on Drug Repurposing and Structural Modification

Molecular Docking and Virtual Screening based prediction of drugs for COVID-19.

In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs

Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2

Predicting drug-Protein interaction with deep learning framework for molecular graphs and sequences: Potential candidates against SAR-CoV-2

MCCS: a Novel Recognition Pattern-Based Method for Fast Track Discovery of Anti-Sars-cov-2 Drugs

Computational Discovery of SARS-CoV-2 Main Protease Inhibitors Via a Virtual Screening, Molecular Docking, Molecular Dynamics and MM/PBSA Calculations-Driven Approach

Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset

Computer-aided drug design for virtual-screening and active-predicting of main protease (Mpro) inhibitors against SARS-CoV-2

In silico Study on Physicochemical, Pharmacokinetic and Toxicity Profiles of Available Antiviral Drugs and The Drug-Target Interaction with Protease of SARS-CoV-2

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Drug repurposing: identification of SARS-CoV-2 potential inhibitors by virtual screening and pharmacokinetics strategies

Genomics Functional Analysis and Drug Screening of SARS-CoV-2